Skip to main content

Table 3 Association of myeloid-derived suppressor cells (MDSCs) and plasmacytoid dendritic cells (pDCs) with melanoma disease course and circulating immune markers

From: Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

  MDSCs pDCs
Melanoma activity and prognosis   
Systemic disease Increased (P = 0.046) Decreased (P = 0.001)
Active disease Increased (P = 0.095) Decreased (P = 0.002)
Death Increased (P = 0.073) Decreased (P = 0.009)
Other immune markers   
CD3 cells Inverse (P < 0.001) None
CD8 cells Inverse (P = 0.017) None
PD-L1+ CD8 cells Positive (P = 0.033) Inverse (P = 0.044)
Regulatory T-cells Inverse (P = 0.007) None
CTLA-4 expression in Tregs Positive (P = 0.003) None
  1. PD-L1, Programmed-Death Ligand 1; CTLA-4, Cytotoxic T Lymphocyte-Associated Antigen 4; Treg, regulatory T-cell.